A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections
To evaluate the efficacy and safety of meropenem in Chinese patients, we conducted a study for the treatment of patients with lower respiratory tract infections, urinary tract infections and other infections. A total of 182 hospitalized patients were enrolled in the study. 90 patients received 500 m...
Gespeichert in:
| Veröffentlicht in: | Chinese medical journal 2002-12, Vol.115 (12), p.1849 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | 1849 |
| container_title | Chinese medical journal |
| container_volume | 115 |
| creator | Hou, Fang Li, Jiatai Wu, Guoping Zheng, Bo Chen, Yifang Gu, Junming Wang, Huiling Huo, Li Xue, Xin Jia, Changxu Yin, Yonghong Tian, Xiaofeng Ren, Shuangyi |
| description | To evaluate the efficacy and safety of meropenem in Chinese patients, we conducted a study for the treatment of patients with lower respiratory tract infections, urinary tract infections and other infections.
A total of 182 hospitalized patients were enrolled in the study. 90 patients received 500 mg meropenem every 12 hours (or 1 g every 12 hours if necessary) and 92 patients received imipenem/cilastatin 500 mg/500 mg every 12 hours (or 1 g every 12 hours if necessary) by intravenous infusion. The duration of treatment was 7 - 14 days for both groups.
Seventy of 90 cases receiving meropenem and 70 of 92 cases receiving imipenem/cilastatin were assessable for clinical efficacy. The overall efficacy rates were 90% for the meropenem group and 87% for the imipenem/cilastatin group, and the bacterial eradication rates were 86% in both groups. 93 (76%) of 123 strains isolated from patients produced beta-lactamases. Adverse drug reactions were evaluated in 72 cases in the meropenem group and 70 cases in the imipenem/cilastatin group. The adverse drug reaction rates were 9.7% and 8.6%, respectively. The results showed that there were no statistical differences between these two groups (P > 0.05).
Meropenem is effective and safe for the treatment of bacterial infections caused mainly by beta-lactamase-producing strains. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_12622937</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>12622937</sourcerecordid><originalsourceid>FETCH-LOGICAL-p207t-8e24e9c3f29f1ca4ffd3ebf6ea5b755a2718acbf1a8edcf2ef5641fe0cbc7bf93</originalsourceid><addsrcrecordid>eNo1kMtOwzAURL0A0VL4BeQPICKxEydeVhUvqRIbWFfXzr3CKLYj20UqX09V6GZGszhnMRdsWUulKqW1XrDrnL_qWnRdr67YohFKCC37JTuseYIwRu9-cLznNoaS4jThyO3kgrMw8ZLcMWPgHlOcMaDn35jyPnPn3Wk_WDdBLlBc4BQTL594pBCKx1B4JG7AFjxpXCC0xcWQb9glwZTx9r9X7OPp8X3zUm3fnl836201i7ov1YCiRW0lCU2NhZZolGhIIXSm7zoQfTOANdTAgKMlgdSptiGsrbG9IS1X7O7PO--Nx3E3J-chHXbnD-QvPGZcfQ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Hou, Fang ; Li, Jiatai ; Wu, Guoping ; Zheng, Bo ; Chen, Yifang ; Gu, Junming ; Wang, Huiling ; Huo, Li ; Xue, Xin ; Jia, Changxu ; Yin, Yonghong ; Tian, Xiaofeng ; Ren, Shuangyi</creator><creatorcontrib>Hou, Fang ; Li, Jiatai ; Wu, Guoping ; Zheng, Bo ; Chen, Yifang ; Gu, Junming ; Wang, Huiling ; Huo, Li ; Xue, Xin ; Jia, Changxu ; Yin, Yonghong ; Tian, Xiaofeng ; Ren, Shuangyi</creatorcontrib><description>To evaluate the efficacy and safety of meropenem in Chinese patients, we conducted a study for the treatment of patients with lower respiratory tract infections, urinary tract infections and other infections.
A total of 182 hospitalized patients were enrolled in the study. 90 patients received 500 mg meropenem every 12 hours (or 1 g every 12 hours if necessary) and 92 patients received imipenem/cilastatin 500 mg/500 mg every 12 hours (or 1 g every 12 hours if necessary) by intravenous infusion. The duration of treatment was 7 - 14 days for both groups.
Seventy of 90 cases receiving meropenem and 70 of 92 cases receiving imipenem/cilastatin were assessable for clinical efficacy. The overall efficacy rates were 90% for the meropenem group and 87% for the imipenem/cilastatin group, and the bacterial eradication rates were 86% in both groups. 93 (76%) of 123 strains isolated from patients produced beta-lactamases. Adverse drug reactions were evaluated in 72 cases in the meropenem group and 70 cases in the imipenem/cilastatin group. The adverse drug reaction rates were 9.7% and 8.6%, respectively. The results showed that there were no statistical differences between these two groups (P > 0.05).
Meropenem is effective and safe for the treatment of bacterial infections caused mainly by beta-lactamase-producing strains.</description><identifier>ISSN: 0366-6999</identifier><identifier>PMID: 12622937</identifier><language>eng</language><publisher>China</publisher><subject>Adult ; Aged ; Alanine Transaminase - blood ; Aspartate Aminotransferases - blood ; Cilastatin - administration & dosage ; Cilastatin - adverse effects ; Cilastatin - therapeutic use ; Female ; Humans ; Imipenem - administration & dosage ; Imipenem - adverse effects ; Imipenem - therapeutic use ; Male ; Middle Aged ; Respiratory Tract Infections - drug therapy ; Thienamycins - adverse effects ; Thienamycins - therapeutic use ; Urinary Tract Infections - drug therapy</subject><ispartof>Chinese medical journal, 2002-12, Vol.115 (12), p.1849</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12622937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hou, Fang</creatorcontrib><creatorcontrib>Li, Jiatai</creatorcontrib><creatorcontrib>Wu, Guoping</creatorcontrib><creatorcontrib>Zheng, Bo</creatorcontrib><creatorcontrib>Chen, Yifang</creatorcontrib><creatorcontrib>Gu, Junming</creatorcontrib><creatorcontrib>Wang, Huiling</creatorcontrib><creatorcontrib>Huo, Li</creatorcontrib><creatorcontrib>Xue, Xin</creatorcontrib><creatorcontrib>Jia, Changxu</creatorcontrib><creatorcontrib>Yin, Yonghong</creatorcontrib><creatorcontrib>Tian, Xiaofeng</creatorcontrib><creatorcontrib>Ren, Shuangyi</creatorcontrib><title>A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections</title><title>Chinese medical journal</title><addtitle>Chin Med J (Engl)</addtitle><description>To evaluate the efficacy and safety of meropenem in Chinese patients, we conducted a study for the treatment of patients with lower respiratory tract infections, urinary tract infections and other infections.
A total of 182 hospitalized patients were enrolled in the study. 90 patients received 500 mg meropenem every 12 hours (or 1 g every 12 hours if necessary) and 92 patients received imipenem/cilastatin 500 mg/500 mg every 12 hours (or 1 g every 12 hours if necessary) by intravenous infusion. The duration of treatment was 7 - 14 days for both groups.
Seventy of 90 cases receiving meropenem and 70 of 92 cases receiving imipenem/cilastatin were assessable for clinical efficacy. The overall efficacy rates were 90% for the meropenem group and 87% for the imipenem/cilastatin group, and the bacterial eradication rates were 86% in both groups. 93 (76%) of 123 strains isolated from patients produced beta-lactamases. Adverse drug reactions were evaluated in 72 cases in the meropenem group and 70 cases in the imipenem/cilastatin group. The adverse drug reaction rates were 9.7% and 8.6%, respectively. The results showed that there were no statistical differences between these two groups (P > 0.05).
Meropenem is effective and safe for the treatment of bacterial infections caused mainly by beta-lactamase-producing strains.</description><subject>Adult</subject><subject>Aged</subject><subject>Alanine Transaminase - blood</subject><subject>Aspartate Aminotransferases - blood</subject><subject>Cilastatin - administration & dosage</subject><subject>Cilastatin - adverse effects</subject><subject>Cilastatin - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Imipenem - administration & dosage</subject><subject>Imipenem - adverse effects</subject><subject>Imipenem - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Respiratory Tract Infections - drug therapy</subject><subject>Thienamycins - adverse effects</subject><subject>Thienamycins - therapeutic use</subject><subject>Urinary Tract Infections - drug therapy</subject><issn>0366-6999</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtOwzAURL0A0VL4BeQPICKxEydeVhUvqRIbWFfXzr3CKLYj20UqX09V6GZGszhnMRdsWUulKqW1XrDrnL_qWnRdr67YohFKCC37JTuseYIwRu9-cLznNoaS4jThyO3kgrMw8ZLcMWPgHlOcMaDn35jyPnPn3Wk_WDdBLlBc4BQTL594pBCKx1B4JG7AFjxpXCC0xcWQb9glwZTx9r9X7OPp8X3zUm3fnl836201i7ov1YCiRW0lCU2NhZZolGhIIXSm7zoQfTOANdTAgKMlgdSptiGsrbG9IS1X7O7PO--Nx3E3J-chHXbnD-QvPGZcfQ</recordid><startdate>200212</startdate><enddate>200212</enddate><creator>Hou, Fang</creator><creator>Li, Jiatai</creator><creator>Wu, Guoping</creator><creator>Zheng, Bo</creator><creator>Chen, Yifang</creator><creator>Gu, Junming</creator><creator>Wang, Huiling</creator><creator>Huo, Li</creator><creator>Xue, Xin</creator><creator>Jia, Changxu</creator><creator>Yin, Yonghong</creator><creator>Tian, Xiaofeng</creator><creator>Ren, Shuangyi</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200212</creationdate><title>A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections</title><author>Hou, Fang ; Li, Jiatai ; Wu, Guoping ; Zheng, Bo ; Chen, Yifang ; Gu, Junming ; Wang, Huiling ; Huo, Li ; Xue, Xin ; Jia, Changxu ; Yin, Yonghong ; Tian, Xiaofeng ; Ren, Shuangyi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p207t-8e24e9c3f29f1ca4ffd3ebf6ea5b755a2718acbf1a8edcf2ef5641fe0cbc7bf93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alanine Transaminase - blood</topic><topic>Aspartate Aminotransferases - blood</topic><topic>Cilastatin - administration & dosage</topic><topic>Cilastatin - adverse effects</topic><topic>Cilastatin - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Imipenem - administration & dosage</topic><topic>Imipenem - adverse effects</topic><topic>Imipenem - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Respiratory Tract Infections - drug therapy</topic><topic>Thienamycins - adverse effects</topic><topic>Thienamycins - therapeutic use</topic><topic>Urinary Tract Infections - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hou, Fang</creatorcontrib><creatorcontrib>Li, Jiatai</creatorcontrib><creatorcontrib>Wu, Guoping</creatorcontrib><creatorcontrib>Zheng, Bo</creatorcontrib><creatorcontrib>Chen, Yifang</creatorcontrib><creatorcontrib>Gu, Junming</creatorcontrib><creatorcontrib>Wang, Huiling</creatorcontrib><creatorcontrib>Huo, Li</creatorcontrib><creatorcontrib>Xue, Xin</creatorcontrib><creatorcontrib>Jia, Changxu</creatorcontrib><creatorcontrib>Yin, Yonghong</creatorcontrib><creatorcontrib>Tian, Xiaofeng</creatorcontrib><creatorcontrib>Ren, Shuangyi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Chinese medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hou, Fang</au><au>Li, Jiatai</au><au>Wu, Guoping</au><au>Zheng, Bo</au><au>Chen, Yifang</au><au>Gu, Junming</au><au>Wang, Huiling</au><au>Huo, Li</au><au>Xue, Xin</au><au>Jia, Changxu</au><au>Yin, Yonghong</au><au>Tian, Xiaofeng</au><au>Ren, Shuangyi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections</atitle><jtitle>Chinese medical journal</jtitle><addtitle>Chin Med J (Engl)</addtitle><date>2002-12</date><risdate>2002</risdate><volume>115</volume><issue>12</issue><spage>1849</spage><pages>1849-</pages><issn>0366-6999</issn><abstract>To evaluate the efficacy and safety of meropenem in Chinese patients, we conducted a study for the treatment of patients with lower respiratory tract infections, urinary tract infections and other infections.
A total of 182 hospitalized patients were enrolled in the study. 90 patients received 500 mg meropenem every 12 hours (or 1 g every 12 hours if necessary) and 92 patients received imipenem/cilastatin 500 mg/500 mg every 12 hours (or 1 g every 12 hours if necessary) by intravenous infusion. The duration of treatment was 7 - 14 days for both groups.
Seventy of 90 cases receiving meropenem and 70 of 92 cases receiving imipenem/cilastatin were assessable for clinical efficacy. The overall efficacy rates were 90% for the meropenem group and 87% for the imipenem/cilastatin group, and the bacterial eradication rates were 86% in both groups. 93 (76%) of 123 strains isolated from patients produced beta-lactamases. Adverse drug reactions were evaluated in 72 cases in the meropenem group and 70 cases in the imipenem/cilastatin group. The adverse drug reaction rates were 9.7% and 8.6%, respectively. The results showed that there were no statistical differences between these two groups (P > 0.05).
Meropenem is effective and safe for the treatment of bacterial infections caused mainly by beta-lactamase-producing strains.</abstract><cop>China</cop><pmid>12622937</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0366-6999 |
| ispartof | Chinese medical journal, 2002-12, Vol.115 (12), p.1849 |
| issn | 0366-6999 |
| language | eng |
| recordid | cdi_pubmed_primary_12622937 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Alanine Transaminase - blood Aspartate Aminotransferases - blood Cilastatin - administration & dosage Cilastatin - adverse effects Cilastatin - therapeutic use Female Humans Imipenem - administration & dosage Imipenem - adverse effects Imipenem - therapeutic use Male Middle Aged Respiratory Tract Infections - drug therapy Thienamycins - adverse effects Thienamycins - therapeutic use Urinary Tract Infections - drug therapy |
| title | A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T05%3A20%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20randomized,%20controlled%20clinical%20trial%20on%20meropenem%20versus%20imipenem/cilastatin%20for%20the%20treatment%20of%20bacterial%20infections&rft.jtitle=Chinese%20medical%20journal&rft.au=Hou,%20Fang&rft.date=2002-12&rft.volume=115&rft.issue=12&rft.spage=1849&rft.pages=1849-&rft.issn=0366-6999&rft_id=info:doi/&rft_dat=%3Cpubmed%3E12622937%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12622937&rfr_iscdi=true |